ABBV.US (ABBV.US) lays out $2 billion to develop drugs for mental illness

AbbVie/ABBV.us (AbbVie/ABBV.us) and Gilgamesh Pharmaceuticals announced a collaboration and licensing option agreement to develop next-generation treatments for mental illness.

Zhitong Finance29minutes ago

Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In

Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This growth would be primarily fueled by the expansion of ad

Benzinga01:32

Unpacking the Latest Options Trading Trends in AbbVie

Deep-pocketed investors have adopted a bearish approach towards AbbVie (NYSE:ABBV), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ABBV usually suggests something big is about to happen.

Benzinga01:31

AbbVie (ABBV) Boosts Neuropsychiatric Portfolio With New Deal

Yahoo Finance00:10

Investors Heavily Search AbbVie Inc. (ABBV): Here Is What You Need to Know

Yahoo FinanceMay 14 21:00

Buy Rating Affirmed: AbbVie's Promising Growth Trajectory and Financial Outlook

TipRanksMay 14 18:55